Prognostic value of proadrenomedullin in patients with COVID-19 pneumonia

The aim of the study was to assess the role of mid-regional proadrenomedullin (MR-proADM) in comparison with routine laboratory tests in patients with COVID-19.140 hospitalized patients aged 18 and older with COVID-19 pneumonia were included in prospective single-center study. Routine analyses were performed, and MR-proADM level was measured within the first and the third hospital days using Human MR pro-ADM (Mid-regional pro-adrenomedullin) ELISA Kit with a sensitivity of 0.469 pmol/L (immunofluorescence assay). National Early Warning Score (NEWS) was used for primary assessment of the disease severity. According to disease outcome the patients were divided into two groups: discharged patients (n = 110, 78.6%) and deceased patients (n = 30, 21.4%). Results: The groups had no statistically significant difference in sex, comorbidity, body temperature, oxygen saturation level, heart rate, respiratory rate, and C-reactive protein (CRP) level and procalcitonin (PCT). The deceased patients had statistically significant difference in age (median, 76 years; interquartile range, 73.2–78.2 vs. median, 66 years; interquartile range, 62–67; p < 0.0001), NEWS value (median, 5; interquartile range, 3–8 vs. median, 2; interquartile range, 0–6; p <0.05), hospitalization period (median, 17; interquartile range, 7–35 vs. median, 6; interquartile range, 3–14), quantitative CT extent of lung damage > 50% [n = 26 (86.7%) vs. n = 9 (8.2%) p < 0.0001], level of leukocytes (median, 11.4 ×109/L; interquartile range, 6.2–15.5 vs. median, 5.3 ×109/L; interquartile range, 4.7–6.4; p = 0.003), level of neutrophils (median, 80.9%; interquartile range, 73.6–88.6 vs. median, 72.6%; interquartile range, 68.7–76.9; p = 0.027), level of MR-proADM at the first hospital day (median, 828.6 pmol/L; interquartile range, 586.4–1,184.6 vs. median, 492.6 pmol/L; interquartile range, 352.9–712.2; p = 0.02), and level of MR-proADM at the third hospital day (median, 1,855.2 pmol/L; interquartile range, 1,078.4–2,596.5 vs. median, 270.7 pmol/L; interquartile range, 155.06–427.1).Mid-regional proadrenomedullin has a higher prognostic value in patients with COVID-19 in comparison with routine inflammatory markers (leukocyte and neutrophils levels, CRP, and PCT) and NEWS.

[1]  M. Barbagallo,et al.  Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19 , 2021, Laboratory medicine.

[2]  P. Schuetz,et al.  The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study , 2021, Clinical chemistry and laboratory medicine.

[3]  A. Rutjes,et al.  Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis , 2020, Critical Care.

[4]  M. Ciaccio,et al.  Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19) , 2020, Diagnosis.

[5]  A. Harky,et al.  The role of biomarkers in diagnosis of COVID-19 – A systematic review , 2020, Life Sciences.

[6]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[7]  J. Legramante,et al.  Procalcitonin and MR-proAdrenomedullin combination in the etiological diagnosis and prognosis of sepsis and septic shock. , 2019, Microbial pathogenesis.

[8]  D. Stolz,et al.  Biomarkers in Pneumonia—Beyond Procalcitonin , 2019, International journal of molecular sciences.

[9]  A. Mebazaa,et al.  Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study , 2018, Critical Care.

[10]  A. Beck‐Sickinger,et al.  Adrenomedullin – new perspectives of a potent peptide hormone , 2017, Journal of peptide science : an official publication of the European Peptide Society.

[11]  J. Quenot,et al.  Superior accuracy of mid-regional proadrenomedullin for mortality prediction in sepsis with varying levels of illness severity , 2017, Annals of Intensive Care.

[12]  J. Paiva,et al.  Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia? , 2016, Revista portuguesa de pneumologia.

[13]  Adil Rafiq Rather,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) , 2015 .

[14]  A. Bilbao,et al.  Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia. , 2015, The Journal of infection.

[15]  T. Welte,et al.  Prediction of in-hospital death from community-acquired pneumonia by varying CRB-age groups , 2012, European Respiratory Journal.

[16]  Jiang Gu,et al.  Pathology and Pathogenesis of Severe Acute Respiratory Syndrome , 2007, The American Journal of Pathology.

[17]  N. Suttorp,et al.  Adrenomedullin reduces vascular hyperpermeability and improves survival in rat septic shock , 2007, Intensive Care Medicine.

[18]  J. Struck,et al.  Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397] , 2006, Critical care.

[19]  J. Struck,et al.  Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. , 2005, Clinical chemistry.

[20]  D. Diz,et al.  Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2 , 2005, Circulation.

[21]  K. Lynn,et al.  Hypotensive and Natriuretic Actions of Adrenomedullin in Subjects With Chronic Renal Impairment , 2001, Hypertension.

[22]  Y. Koiwaya,et al.  Secretion and clearance of the mature form of adrenomedullin in humans. , 1999, Life sciences.

[23]  N. Arakawa,et al.  Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. , 1997, Circulation.

[24]  K. Hirata,et al.  Adrenomedullin inhibits the secretion of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, from rat alveolar macrophages. , 1995, Biochemical and biophysical research communications.

[25]  K. Kangawa,et al.  Plasma adrenomedullin concentration in patients with heart failure. , 1996, The Journal of clinical endocrinology and metabolism.